83 Results for "

DIO

" in MedChemExpress (MCE) Product Catalog:
Products (83)

83 Results for "DIO" in MCE Product Catalog:

29
29 Publications Verification
Cat. No.: HY-D0969
CAS No.: 34215-57-1
Synonyms: DIOC18(3); 3,3'-DIOctadecyloxacarbocyanine perchlorate
DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-18341
CAS No.: 51-48-9
Synonyms: Levothyroxine; T4
L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18341B
CAS No.: 55-03-8
Synonyms: Levothyroxine sodium; T4 sodium
L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18341A
CAS No.: 6106-07-6
Synonyms: Sodium levothyroxine pentahydrate
L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-W010669
CAS No.: 25416-65-3
Synonyms: Sodium levothyroxine
L-Thyroxine sodium xhydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0346
CAS No.: 51-52-5
Synonyms: 6-n-Propylthiouracil; 6-Propyl-2-thiouracil; PTU
Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13467
CAS No.: 1142214-62-7
Purity:  99.65%
Research Areas:  

Metabolic Disease

AM-1638 is an orally active full agonist of GPR40 (EC50: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14342
CAS No.: 1022152-70-0
Purity:  99.75%
Target:  

Bombesin Receptor

Research Areas:  

Metabolic Disease

MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P4860
CAS No.: 1802086-30-1
Target:  

Akt Gli JNK PKA

Research Areas:  

Metabolic Disease

Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120103
CAS No.: 1854061-16-7
Purity:  99.51%
Target:  

Sodium Channel

Research Areas:  

Metabolic Disease

PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
loading...
    loading...
Cat. No.: HY-P10745
CAS No.: 2766385-23-1
Synonyms: ZP8396
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
loading...
    loading...
Cat. No.: HY-P10745A
Synonyms: ZP8396 acetate
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
loading...
    loading...
Cat. No.: HY-12443
CAS No.: 1293395-67-1
Purity:  99.56%
Target:  

Casein Kinase

Research Areas:  

Neurological Disease

PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
loading...
    loading...
Cat. No.: HY-151500
CAS No.: 3026599-90-3
Purity:  99.20%
Research Areas:  

Metabolic Disease

JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
loading...
    loading...
Cat. No.: HY-160912
CAS No.: 1135000-36-0
Target:  

ELOVL

Research Areas:  

Metabolic Disease

ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC50 values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .
loading...
    loading...
Cat. No.: HY-18341R
CAS No.: 51-48-9
Synonyms: Levothyroxine (Standard); T4 (Standard)
L-Thyroxine (Standard) is the analytical standard of L-Thyroxine. This product is intended for research and analytical applications. L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
loading...
    loading...
Cat. No.: HY-U00425
CAS No.: 1264754-13-3
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC50 values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .
loading...
    loading...
Cat. No.: HY-114557
CAS No.: 1041-01-6
Purity:  99.38%
Synonyms: 3,5-Diiodo-L-thyronine
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
loading...
    loading...
Cat. No.: HY-P10302A
Target:  

GLP Receptor

GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
loading...
    loading...
Cat. No.: HY-147318
CAS No.: 1454662-41-9
Purity:  99.55%
Target:  

Apoptosis

Research Areas:  

Cancer

PBENZ-DBRMD is a potent iodothyronine deiodinase type 3 (DIO3) inhibitor. PBENZ-DBRMD has anti-proliferative activity and induces apoptosis. PBENZ-DBRMD can be used for cancer research .
loading...
    loading...